Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病B-ALL
A leukaemia or lymphoma of immature B cells, found mainly in children and adolescents, with a high number of lymphoblasts. It most often appears as leukaemia.
Definition adapted from MeSH (US National Library of Medicine)
- hospitals in mainland China
- 90
- cities
- 37
with a paper from 2016–2025 or a registered study
where those hospitals are
Mainland China accounts for 23% of the world's English-language research papers on B-cell acute lymphoblastic leukaemia, 2021–2025 (12% in 2016–2020), and 16% of the world's registered trials on it have a site in China.
Research activity in public records, not a rating of care and not medical advice. How the numbers are made
90 hospitals in 37 cities
Order: papers led on B-cell acute lymphoblastic leukaemia, 2021–2025, then A–Z. Research activity, not a rating of care.
A hospital is listed when it led at least 2 papers or 1 trial on B-cell acute lymphoblastic leukaemia, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions
Cities with the most listed hospitals
Each opens B-cell acute lymphoblastic leukaemia in that city. 27 more cities are in the menu below.
- 19 papers led
- 13 papers led
- 12 papers led
- 11 papers led
- 8 papers ledNo open trial led
- 8 papers led
- 7 papers ledNo open trial led
- 7 papers led
- 5 papers ledNo open trial led
- 5 papers led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers ledNo open trial led
- 3 papers led
- 3 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 1 paper led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
- 0 papers led
- 0 papers led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
No listed hospital matches these filters.
By university or health system 41
Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.
- 20 papers led3 hospitals
- 19 papers led1 hospital
- 15 papers led2 hospitals
- 15 papers led2 hospitals
- 11 papers led3 hospitals
- 10 papers led5 hospitals
- 10 papers led2 hospitals
- 9 papers led2 hospitals
- 7 papers led3 hospitals
- 5 papers led2 hospitals
- 5 papers led1 hospital
- 4 papers led1 hospital
- 4 papers led1 hospital
- 3 papers led1 hospital
- 3 papers led1 hospital
- 3 papers led3 hospitals
- 3 papers led2 hospitals
- 3 papers led2 hospitals
- 3 papers led2 hospitals
- 3 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led1 hospital
- 2 papers led2 hospitals
- 1 paper led1 hospital
- 1 paper led1 hospital
- 0 papers led0 hospitals
- 0 papers led0 hospitals
- 0 papers led0 hospitals
- 0 papers led0 hospitals
- 0 papers led0 hospitals
- 0 papers led0 hospitals
- 0 papers led0 hospitals
- 0 papers led0 hospitals
open trials on B-cell acute lymphoblastic leukaemia in China
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 73 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.
Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial
What the phases mean (US National Cancer Institute)
- RecruitingSafety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
- Phase
- Phase 1
- Started
- 2026-03
- Registry
- NCT06326008
Age 1 year to 18 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingKSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-01
- Registry
- NCT07246707
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2026-02
- Registry
- NCT07429461
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
- Phase
- Early phase 1
- Started
- 2026-04
- Registry
- NCT07470073
Age 12 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingTargeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07575919
Age 18 years to 85 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingExploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07575971
Age 18 years to 85 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingPhase I Study of FXS0683 in the Treatment of Blood Tumors
- Phase
- Phase 1
- Started
- 2026-06
- Registry
- NCT07616089
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingDual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07838714
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingBEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-09
- Registry
- NCT07854652
Age 14 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingGN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-08
- Registry
- NCT07910708
Age 18 years to 75 years (registered criteria)
Led by Pu'er People's HospitalPu'er
- RecruitingTCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Registry
- NCT06481735
Age 16 years to 70 years (registered criteria)
Led by Chinese PLA General Hospital; 3 listed hospitals as study sitesBeijing, Tianjin
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06689917
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalWuhan
- RecruitingNewly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Registry
- NCT06764238
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingDonor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06793241
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNewly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Registry
- NCT06882057
Age 1 year to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2025-03
- Registry
- NCT06890065
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingClinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
- Phase
- Early phase 1
- Started
- 2025-01
- Registry
- NCT06890494
Age 18 years to 70 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2025-05
- Registry
- NCT06940960
Age 12 years to 75 years (registered criteria)
Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang
- RecruitingIntravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
- Phase
- N/A
- Started
- 2025-04
- Registry
- NCT06961669
Age 3 years to Not stated (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingFull-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
- Phase
- Phase 2
- Started
- 2025-05
- Registry
- NCT06985485
Age 15 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingBlinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
- Phase
- N/A
- Started
- 2025-02
- Registry
- NCT07003737
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingBCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Registry
- NCT07008885
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingCD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT07072494
Age 14 years to 80 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- RecruitingEffectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Started
- 2025-08
- Registry
- NCT07105579
Age 14 years to 65 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingCD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-06
- Registry
- NCT07106749
Age 18 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingNewly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT07152041
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan
- RecruitingA Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- Phase
- Early phase 1
- Started
- 2025-09
- Registry
- NCT07205315
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingAssessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
- Phase
- Phase 2
- Started
- 2025-01
- Registry
- NCT07244406
Age 3 years to 25 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingCD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
- Phase
- Phase 3
- Started
- 2025-11
- Registry
- NCT07441291
Age 3 years to 79 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingFull-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Started
- 2025-04
- Registry
- NCT07564453
Age 15 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingLow-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07763054
Age 18 years to 75 years (registered criteria)
Led by Affiliated Hospital of Central South UniversityHaikou
- RecruitingThiotepa, Cyclophosphamide, Clarithromycin and Cytarabine
- Phase
- Phase 1
- Started
- 2024-03
- Registry
- NCT06060782
Age 18 years to 65 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai
- RecruitingCAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT06179524
Age Not stated to 25 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin
- RecruitingRDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
- Phase
- Phase 2
- Started
- 2024-02
- Registry
- NCT06250959
Age 15 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingThe Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2024-03
- Registry
- NCT06307600
Age 3 years to 70 years (registered criteria)
Led by First Affiliated Hospital of USTC; 1 listed hospital as study siteHefei, Wuhan
- RecruitingClinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
- Phase
- N/A
- Started
- 2024-04
- Registry
- NCT06343090
Age 1 year to 70 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingCD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
- Phase
- Early phase 1
- Started
- 2024-05
- Registry
- NCT06346912
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingCD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
- Phase
- N/A
- Started
- 2024-02
- Registry
- NCT06355739
Age 3 years to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06387121
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingCIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
- Phase
- N/A
- Started
- 2024-05
- Registry
- NCT06389305
Age 1 year to 39 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingDecitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
- Phase
- Phase 2
- Started
- 2024-04
- Registry
- NCT06393985
Age 18 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingCD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
- Phase
- Phase 1
- Started
- 2024-05
- Registry
- NCT06445803
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanchang, Shanghai
- RecruitingInaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Phase
- Not given
- Started
- 2024-06
- Registry
- NCT06450067
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingEfficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06481228
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingEfficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06481241
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingBlinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
- Phase
- Phase 1
- Started
- 2024-04
- Registry
- NCT06507514
Age 15 years to 65 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingBlinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06554626
Age 40 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStudy of YK012 in B-cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Registry
- NCT06580301
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Guangzhou, Guiyang, Hangzhou, Nanchang, Xuzhou
- RecruitingBridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
- Phase
- N/A
- Started
- 2024-10
- Registry
- NCT06581081
Age 12 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingEfficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Registry
- NCT06607419
Age 1 month to 18 years (registered criteria)
Led by Shanghai Children's Medical Center; 1 listed hospital as study siteHefei, Shanghai
- RecruitingCombination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06608732
Age 16 years to 70 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- RecruitingAllogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2024-12
- Registry
- NCT06696833
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingInaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06718244
Age 16 years to 70 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Registry
- NCT06735495
Age 3 years to 75 years (registered criteria)
Led by Union HospitalWuhan
- RecruitingBlinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
- Phase
- Phase 2
- Started
- 2024-10
- Registry
- NCT06742515
Age 15 years to 59 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingCD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
- Phase
- Phase 1
- Started
- 2024-10
- Registry
- NCT06752785
Age 1 year to 18 years (registered criteria)
Led by Guangzhou Women and Children's Medical CenterGuangzhou
- RecruitingVenetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
- Phase
- Phase 2
- Started
- 2024-12
- Registry
- NCT06754267
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Registry
- NCT06880913
Age 12 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingThe Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Registry
- NCT06911710
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingA Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- Phase
- Phase 1
- Started
- 2024-09
- Registry
- NCT06927466
Age 3 years to 25 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Suzhou, Wuhan, Xuzhou
- RecruitingEfficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Registry
- NCT07584889
Age 18 years to 75 years (registered criteria)
Led by Shenzhen University General HospitalShenzhen
- RecruitingBlinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
- Phase
- Phase 1
- Started
- 2024-12
- Registry
- NCT07677878
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Registry
- NCT05667506
Age 3 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChongqing, Guangzhou, Hefei, Nanchang, Nanjing, Tianjin, Wuhan, Xuzhou
- RecruitingBlinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation
- Phase
- Phase 4
- Started
- 2023-09
- Registry
- NCT06339775
Age Not stated to 65 years (registered criteria)
Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou
- RecruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
- Phase
- N/A
- Started
- 2023-09
- Registry
- NCT06678282
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou
- RecruitingA Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT05334823
Age 3 years to 21 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou
- RecruitingA Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- Phase
- Phase 1/Phase 2
- Started
- 2022-11
- Registry
- NCT05579132
Age 2 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingCAV Regimen for R/R Ph- B-ALL
- Phase
- N/A
- Started
- 2022-10
- Registry
- NCT05657652
Age 15 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- RecruitingCD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Started
- 2022-01
- Registry
- NCT06081478
Age 14 years to 85 years (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingRuxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen
- Phase
- Phase 2
- Started
- 2021-12
- Registry
- NCT05088226
Age 12 years to 65 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
- Phase
- Early phase 1
- Started
- 2020-01
- Registry
- NCT04227015
Age 3 years to 70 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingPhase Ib Clinical Study of Keynatinib
- Phase
- Phase 1
- Started
- 2020-09
- Registry
- NCT04807881
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Shanghai
- Not yet recruitingClinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07491263
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- Not yet recruitingU96-CAR-T-Cells For R/R B-ALL
- Phase
- Phase 1
- Started
- 2026-07
- Registry
- NCT07511426
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingEvaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
- Phase
- Phase 1
- Started
- 2026-04
- Registry
- NCT07539610
Age 18 years to 69 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingClinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
- Phase
- Early phase 1
- Started
- 2026-08
- Registry
- NCT07696481
Age 3 years to 75 years (registered criteria)
Led by Zhujiang HospitalGuangzhou
- Not yet recruitingSNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- Phase
- Early phase 1
- Started
- 2026-09
- Registry
- NCT07830238
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangchun
- Not yet recruitingImmunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07840976
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingBusulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
- Phase
- N/A
- Started
- 2026-11
- Registry
- NCT07919470
Age 14 years to 65 years (registered criteria)
Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Langfang
- Not yet recruitingEffectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06861348
Age 14 years to 65 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingJY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
- Phase
- N/A
- Started
- 2025-03
- Registry
- NCT06902025
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingA Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07043218
Age 18 years to 75 years (registered criteria)
Led by Tongji HospitalShanghai
- Not yet recruitingEx Vivo T-Cell-Depleted Haploidentical Transplantation Bridging With Chimeric Antigen Receptor T-cell Therapy and Prophylactic Memory T Cell Infusion for Acute Leukemia
- Phase
- N/A
- Started
- 2025-09
- Registry
- NCT07087847
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingRN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07113496
Age 18 years to Not stated (registered criteria)
Led by Jiangsu Province HospitalNanjing
- Not yet recruitingA Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07234045
Age 18 years to 75 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin
- Not yet recruitingBEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07301138
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingHema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
- Phase
- Early phase 1
- Started
- 2024-09
- Registry
- NCT06559644
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Soochow UniversitySuzhou
- Not yet recruitingClinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06641024
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingCD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
- Phase
- Early phase 1
- Started
- 2020-11
- Registry
- NCT04609241
Age not stated (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Before contacting a hospital
The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.
- How to startTalk with the treating doctor, prepare the records hospitals ask for, then write to two or three hospitals.
- Questions to check before asking about a trialWhat the registered criteria usually ask about, and what to ask the study team.
- Common questionsInternational patients, costs, trials and visas.
National guideline (China)
- Standards for childhood acute lymphoblastic and acute promyelocytic leukaemia (2018 edition)National Health Commission 国卫办医函〔2018〕868号, 2018-10-16; children
Written for doctors, in Chinese. We link to the official notice only and do not summarise it; it is not medical advice.
Where these numbers come from
Papers
225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search
Trials
ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.